Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tanaka, Hiroshi
SWIFT-2, NCT04718103 / 2020-003611-10: A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype Jul 2024 - Dec 2024 : H2'24 - Acceptance of regulatory submission in US (based on SWIFT-1 trial) for asthma	Completed	3	397	Europe, Canada, Japan, US, RoW	GSK3511294, Depemokimab, Placebo	GlaxoSmithKline, Iqvia Pty Ltd	Asthma	04/24	04/24
NCT05243680 / 2020-004334-38: An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)	Active, not recruiting	3	641	Europe, Canada, Japan, US, RoW	GSK3511294 (Depemokimab)	GlaxoSmithKline, Iqvia Pty Ltd	Asthma	05/25	05/25
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP	Active, not recruiting	3	1667	Europe, Canada, Japan, US, RoW	GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)	GlaxoSmithKline, Iqvia Pty Ltd	Asthma	10/25	10/25
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)	Recruiting	3	170	Europe, Canada, Japan, US, RoW	Selpercatinib, LY3527723, LOXO-292, Placebo	Loxo Oncology, Inc., Eli Lilly and Company	Carcinoma, Non-Small-Cell Lung	05/27	08/32
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer	Recruiting	1/2	183	Japan, US, RoW	Glumetinib, SCC244	Haihe Biopharma Co., Ltd.	C-Met Exon 14 Mutation	10/23	12/23
REZILIENT1, NCT04036682: A Phase 1/2 Trial of CLN-081 in Patients with Non-Small Cell Lung Cancer Data from a trial for NSCLC Jan 2022 - Jan 2022: Data from a trial for NSCLC	Active, not recruiting	1/2	284	Europe, Japan, US, RoW	CLN-081, TAS6417; zipalertinib	Cullinan Therapeutics Inc.	Non Small Cell Lung Cancer, EGFR Exon 20 Mutation	12/24	12/24